Form 8-K - Current report:
SEC Accession No. 0001493152-24-042964
Filing Date
2024-10-30
Accepted
2024-10-29 21:52:19
Documents
20
Period of Report
2024-10-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 63214
2 ex4-1.htm EX-4.1 132430
3 ex4-2.htm EX-4.2 123499
4 ex4-3.htm EX-4.3 122992
5 ex10-1.htm EX-10.1 279314
6 ex10-2.htm EX-10.2 182220
7 ex99-1.htm EX-99.1 10133
  Complete submission text file 0001493152-24-042964.txt   1318267

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE ptix-20241029.xsd EX-101.SCH 3796
9 XBRL DEFINITION FILE ptix-20241029_def.xml EX-101.DEF 30062
10 XBRL LABEL FILE ptix-20241029_lab.xml EX-101.LAB 36749
11 XBRL PRESENTATION FILE ptix-20241029_pre.xml EX-101.PRE 27085
23 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5651
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 241407173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)